Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions.
Leslie, Jack Geh, Daniel Elsharkawy, Ahmed M Mann, Derek A Vacca, Michele
Leslie, Jack
Geh, Daniel
Elsharkawy, Ahmed M
Mann, Derek A
Vacca, Michele
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2022-02-12
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
HCV hijacks many host metabolic processes in an effort to aid viral replication. The resulting hepatic metabolic dysfunction underpins many of the hepatic and extrahepatic manifestations of chronic hepatitis C (CHC). However, the natural history of CHC is also substantially influenced by the host metabolic status: obesity, insulin resistance and hepatic steatosis are major determinants of CHC progression toward hepatocellular carcinoma (HCC). Direct-acting antivirals (DAAs) have transformed the treatment and natural history of CHC. While DAA therapy effectively eradicates the virus, the long-lasting overlapping metabolic disease can persist, especially in the presence of obesity, increasing the risk of liver disease progression. This review covers the mechanisms by which HCV tunes hepatic and systemic metabolism, highlighting how systemic metabolic disturbance, lipotoxicity and chronic inflammation favour disease progression and a precancerous niche. We also highlight the therapeutic implications of sustained metabolic dysfunction following sustained virologic response as well as considerations for patients who develop HCC on the background of metabolic dysfunction.
Citation
Leslie J, Geh D, Elsharkawy AM, Mann DA, Vacca M. Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions. J Hepatol. 2022 Jul;77(1):219-236. doi: 10.1016/j.jhep.2022.01.029. Epub 2022 Feb 12
Type
Article